CALC
Price
$1.62
Change
-$0.02 (-1.22%)
Updated
Oct 2 closing price
Capitalization
11.47M
47 days until earnings call
Intraday BUY SELL Signals
OBIO
Price
$5.95
Change
-$0.40 (-6.30%)
Updated
Oct 2 closing price
Capitalization
354.02M
45 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CALC vs OBIO

CALC vs OBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CALC vs. OBIO commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CALC is a Hold and OBIO is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
CALC vs OBIO: Fundamental Ratings
CALC
OBIO
OUTLOOK RATING
1..100
7039
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
62
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9335
P/E GROWTH RATING
1..100
3100
SEASONALITY SCORE
1..100
4975

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CALC's Valuation (25) in the null industry is somewhat better than the same rating for OBIO (62). This means that CALC’s stock grew somewhat faster than OBIO’s over the last 12 months.

CALC's Profit vs Risk Rating (100) in the null industry is in the same range as OBIO (100). This means that CALC’s stock grew similarly to OBIO’s over the last 12 months.

CALC's SMR Rating (100) in the null industry is in the same range as OBIO (100). This means that CALC’s stock grew similarly to OBIO’s over the last 12 months.

OBIO's Price Growth Rating (35) in the null industry is somewhat better than the same rating for CALC (93). This means that OBIO’s stock grew somewhat faster than CALC’s over the last 12 months.

CALC's P/E Growth Rating (3) in the null industry is significantly better than the same rating for OBIO (100). This means that CALC’s stock grew significantly faster than OBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CALCOBIO
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 2 days ago
56%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
67%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
65%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
59%
Advances
ODDS (%)
Bullish Trend about 1 month ago
82%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 10 days ago
79%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
68%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (CALC: $1.64 vs. OBIO: $6.35)
Brand notoriety: CALC and OBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CALC: 35% vs. OBIO: 100%
Market capitalization -- CALC: $11.47M vs. OBIO: $354.02M
CALC [@Biotechnology] is valued at $11.47M. OBIO’s [@Biotechnology] market capitalization is $354.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CALC’s FA Score shows that 2 FA rating(s) are green while OBIO’s FA Score has 0 green FA rating(s).

  • CALC’s FA Score: 2 green, 3 red.
  • OBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, CALC is a better buy in the long-term than OBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CALC’s TA Score shows that 3 TA indicator(s) are bullish while OBIO’s TA Score has 5 bullish TA indicator(s).

  • CALC’s TA Score: 3 bullish, 6 bearish.
  • OBIO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, OBIO is a better buy in the short-term than CALC.

Price Growth

CALC (@Biotechnology) experienced а -5.75% price change this week, while OBIO (@Biotechnology) price change was +6.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

CALC is expected to report earnings on Nov 18, 2026.

OBIO is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CALC
Daily Signal:
Gain/Loss:
OBIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OPLN34.870.74
+2.17%
OPENLANE Inc.
TRI99.362.03
+2.09%
Thomson Reuters Corp
EIG48.650.91
+1.91%
Employers Holdings
BVFL21.200.22
+1.05%
BV Financial
SCNX0.18-0.08
-31.83%
Scienture Holdings Inc

CALC and

Correlation & Price change

A.I.dvisor tells us that CALC and OBIO have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CALC and OBIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CALC
1D Price
Change %
CALC100%
+1.23%
OBIO - CALC
33%
Poorly correlated
+2.09%
MTNB - CALC
28%
Poorly correlated
-5.10%
ALDX - CALC
26%
Poorly correlated
+4.88%
HIND - CALC
26%
Poorly correlated
-1.04%
LITS - CALC
26%
Poorly correlated
+4.17%
More

OBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, OBIO has been loosely correlated with RXRX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if OBIO jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OBIO
1D Price
Change %
OBIO100%
+2.09%
RXRX - OBIO
35%
Loosely correlated
-1.45%
ABOS - OBIO
33%
Loosely correlated
-6.76%
STOK - OBIO
33%
Poorly correlated
+0.04%
CALC - OBIO
33%
Poorly correlated
+1.23%
RCKT - OBIO
33%
Poorly correlated
-1.52%
More